AstraZeneca and Merck Report Result of Lynparza (olaparib) in P-III POLO Trial for BRCA-Mutated Metastatic Pancreatic Cancer #ASCO2019
Shots:
- The P-III POLO study involves assessing of Lynparza (olaparib- 300mg- bid) vs PBO in 154 patients in ratio (3:2) with BRCAm metastatic pancreatic cancer whose disease had not progressed on 1st-line Pt-based CT
- The P-III POLO study results: improvement in PFS (7.4 vs 3.8mos.); @1yr & 2yrs. no disease progression ( 34% & 22% vs 15% & 10%) respectively
- Lynparza (olaparib) is a PARP inhibitor targeted for DNA damage response (DDR) pathway deficiencies- including BRCA mutations. In 2017- Merck and AstraZeneca collaborated to co-develop and co-commercialize Lynparza globally
Ref: AstraZeneca | Image: AstraZeneca
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com